Zhao, Yuanyuan Ma, Yuxiang Zang, Aimin Cheng, Ying Zhang, Yiping Wang, Xiangcai Chen, Zhendong Qu, Song He, Jianbo Chen, Chuanben
...
Published in
Journal of Hematology & Oncology
Background QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t1/2) for CTLA-4. We report results from a phase I/Ib study of QL1706 in patients with advanced solid tumors who failed stand...
Ni, Wen Zhang, Yuqin Zhan, Zetao Ye, Feng Liang, Yonghao Huang, Jing Chen, Keli Chen, Longhua Ding, Yi
Published in
Journal of Hematology & Oncology
Elnaggar, Muhammad Agte, Sarita Restrepo, Paula Ram, Meghana Melnekoff, David Adamopoulos, Christos Stevens, Mark M. Kappes, Katerina Leshchenko, Violetta Verina, Daniel
...
Published in
Journal of Hematology & Oncology
Epperla, Narendranath Welkie, Rina Li Torka, Pallawi Shouse, Geoffrey Karmali, Reem Shea, Lauren Anampa-Guzmán, Andrea Oh, Timothy S. Reaves, Heather Tavakkoli, Montreh
...
Published in
Journal of Hematology & Oncology
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis-to-treatment interval can be highly variable with no universal criteria to initiate systemic therapy. Hence,...
Chen, Jungang Lin, Zhen Song, Jiao Plaisance-Bonstaff, Karlie James, Jennifer Mu, Shengyu Post, Steven R Dai, Lu Qin, Zhiqiang
Published in
Journal of hematology & oncology
Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), which preferentially arise in immunocompromised patients while lack of effective therapeutic options. Oncoproteins Myc and hypoxia-inducible factor-1α (HIF1α) have been found closely re...
Ye, Xinyu Huang, Xin Fu, Xing Zhang, Xiao Lin, Risheng Zhang, Wen Zhang, Jian Lu, Yi
Published in
Journal of hematology & oncology
Bone metastasis is the leading cause of death in patients with prostate cancer (PCa) and currently has no effective treatment. Disseminated tumor cells in bone marrow often obtain new characteristics to cause therapy resistance and tumor recurrence. Thus, understanding the status of disseminated prostate cancer cells in bone marrow is crucial for d...
Chen, Chen Dai, Liyuan Zheng, Cuiling Li, Haolong Li, Xiaomeng Yang, Mengwei Gao, Ruyun Yao, Jiarui Zhang, Zhishang Shi, Yuankai
...
Published in
Journal of hematology & oncology
COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4/5 after the primary 2-dose and booster vaccination remained unknown. We conducted a cross-sectional study in 260 LCs, 140 healthy controls (HC) and additional 40 LCs with serial samples by detecting total a...
Li, Xinxin Yan, Xianchun Wang, Yufeng Kaur, Balveen Han, Hua Yu, Jianhua
Published in
Journal of Hematology & Oncology
Dysregulation of the Notch signaling pathway, which is highly conserved across species, can drive aberrant epigenetic modification, transcription, and translation. Defective gene regulation caused by dysregulated Notch signaling often affects networks controlling oncogenesis and tumor progression. Meanwhile, Notch signaling can modulate immune cell...
Kantarjian, Hagop Haddad, Fadi G. Jain, Nitin Sasaki, Koji Short, Nicholas J. Loghavi, Sanam Kanagal-Shamanna, Rashmi Jorgensen, Jeffrey Khouri, Issa Kebriaei, Partow
...
Published in
Journal of Hematology & Oncology
Background Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential blinatumomab to low-intensity mini-Hyper-CVD chemotherapy with inotuzumab ozogamicin in this setting. Methods Mini-Hyper-CVD (cyclo...
Jin, Hua Zhang, Yu Yu, Sijian Du, Xin Xu, Na Shao, Ruoyang Lin, Dongjun Chen, Yanqiu Xiao, Jie Sun, Zhiqiang
...
Published in
Journal of Hematology & Oncology
Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringtonine (VAH) regimen for R/R AML. Methods This phase 2 trial was done at ten hospitals in China. Eligible patients were R/R AML (age...
